ELMIRON® provides proven efficacy with interstitial cystitis (IC) pain relief in as soon as 3 months and sustained pain relief over time.


IC may be caused by a breakdown of the protective lining of the bladder—or glycosaminoglycan layer—which may allow potentially irritating solutes in the urine to reach the cells.




download MOA of ELMIRON®
For Windows Compatible Systems Only

Although the mechanism of action of ELMIRON® in interstitial cystitis is not fully understood, ELMIRON® is thought to adhere to the bladder mucosal lining, preventing potentially irritating solutes in the urine from reaching the bladder wall.

ELMIRON® is the only FDA-approved oral therapy indicated for the relief of bladder pain or discomfort associated with IC

ELMIRON® provides relief in as soon as 3 months


  • 61% of patients on monotherapy experienced improvement in symptoms at 3 months on therapy (n=1192)*
    • In patients whose pain has not improved after 6 months of therapy, the clinical relevance and risks of continued treatment are unknown
*1192 of 2499 patients received treatment for 3 months.


ELMIRON® provides sustained pain relief over time


  • In an open-label physician's usage study, 149 patients with IC continued treatment with ELMIRON® for 3 years1
    • Over 60% of these patients reported sustained pain relief for up to 3 years
    Reference:
  1. Hanno PM. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology. 1997;49(suppl 5A):93-99.

Treatment success starts in the exam room: Counsel patients that clinical response may require 3 to 6 months of continuous therapy

  • At 3 months on monotherapy, 61% of patients experienced improvement in symptoms (n=1192)*
  • In patients whose pain has not improved after 6 months of therapy, the clinical relevance and risks of continued treatment are unknown


Counsel patients that symptom improvement is often gradual
  • 55% of patients discontinue ELMIRON® therapy after their first prescription†1
    • 74% discontinue after the third prescription

ELMIRON® Journey to Relief™ program can help
  • An e-mail program developed exclusively for patients who take ELMIRON®
  • Patients can enroll at www.journeytorelief.com

KOL Video: STAY With ELMIRON®

This video features Dr David Kaufman and further discusses the importance of setting patient expectations and counseling patients to stay on ELMIRON® for 3 to 6 months.

With:
David M. Kaufman, MD
Assistant Professor of Clinical Urology,
Columbia University
Central Park Urology
New York, NY
Ortho Women's Health & Urology™ Consultant Speaker


*1192 of 2499 patients received treatment for 3 months.
†Data from a national survey of 8453 patients.
    Reference:
  1. IMS data, January 2007.

The following testimonials are the real-life accounts of ELMIRON ® patients. These patients discuss how they were diagnosed with and treated for IC.



Kristina



Randy



Terry-Jo Myers



Hope